Bristol’s Ixempra (Generic: ixabepilone) was approved for sale by the United States Food and Drug Administration and will be available for sale in the United States within a few days.

The chemotherapy drug is approved for a stand-alone treatment for patients with advanced tumors that do not respond to Xeloda or other drugs with the anthracyclines or taxanes categories.

Two ongoing trials are expected to determine by late 2008 whether Ixempra actually extends survival.

Rating 3.00 out of 5
[?]